Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTI-301 in Advanced Malignancy
NCT06911008Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTI-301 in solid tumor, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose up to 28 days and Incidence of Adverse Events. Started Nov 2025; status: recruiting.
02
Drugs
MTI-301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06911008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911008.